Peggy Johnson, CEO of Agility Robotics, discusses how humanoid robots like Digit are transforming logistics and manufacturing. She speaks with Bloomberg Businessweek’s Brad Stone about the rapid advances in automation and the next era of robots in the workplace at Bloomberg Tech in San Francisco. (Source: Bloomberg)
Can one person run a business like a team of ten? In this episode, we explore how AI empowers solopreneurs to scale faster, automate smarter, and compete at…
Security teams face growing demands with more tools, more data, and higher expectations than ever. Boards approve large security budgets, yet still ask the same question: what is the business getting in return? CISOs respond with reports on controls and vulnerability counts – but executives want to understand risk in terms of financial exposure, operational impact, and avoiding loss.
The disconnect has become difficult to ignore. The average cost of a breach has reached $4.88 million, according to recent IBM data. That figure reflects not just incident response but also downtime, lost productivity, customer attrition, and the extended effort required to restore operations and trust. The fallout is rarely confined to security.
Security leaders need a model that brings those consequences into view before they surface. A Business Value Assessment (BVA) offers that model. It links exposures to cost, prioritization to return, and prevention to tangible value.
More and more people are investing their time and energy into longevity — it’s not just living longer, but living happier, healthier and staying productive well past what has been considered “old age.” McKinsey reports that up to 60 percent of consumers across health and wellness markets say that healthy aging is a “top” or “very important” priority. The movement has created a boost in the health and wellness businesses, and to get an overview of the longevity supplements space, we spoke with Dr. Luke Winegard, the Chief Operating Officer at Longevity Method.
Entrepreneur: What is driving the current boom in the longevity supplement market? Dr. Luke Winegard: Growing consumer demand for health and wellness products is creating explosive growth in the longevity supplement market. Scientific advancements and increasing health consciousness are driving this trend, with consumers now focused on “healthspan” — not just how long they live, but how well they live. The pursuit of longevity has moved from being a niche interest of visionaries to becoming mainstream in 2025.
What does “healthspan” mean and why is it important? Healthspan refers to the period of life spent in good health, free from chronic diseases and disabilities. Today’s consumers are concerned not just about adding years to their lives, but making those years healthy, productive, and vital. This represents a cultural shift toward proactive self-optimization where maintaining energy, cognitive sharpness, and resilience is just as important as achieving physical goals.
Posted in business, economics, law, singularity | Leave a Comment on Iceland approved the 4-day workweek in 2019, nearly 6 years later, all the predictions made by Generation Z have come true
Fewer hours. Same pay. Possible approach to the Economic Singularity?
In 2019, Iceland made headlines by becoming one of the first countries in the world to adopt the four-day working week, not through a general law, but through agreements allowing workers to negotiate shorter weeks or reduced hours. Five years on, the results are indisputable.
The Icelandic experiment began in 2015 with a pilot phase involving around 2,500 employees, or just over 1% of the country’s working population. Following the resounding success of this initiative, with 86% of the employees involved expressing their support, the project was formalised in 2019. Today, almost 90% of Icelandic workers benefit from a reduced working week of 36 hours, compared with 40 hours previously, with no loss of pay.
Initial concerns about the four-day week were widespread, both in Iceland and elsewhere in the world. There were fears of a drop in productivity, increased costs for businesses and difficulties in adapting to maintain service levels. However, the Icelandic experience has swept these fears under the carpet.
High manufacturing costs are limiting patient access to CAR T cell therapies, according to new research, which indicates that decentralization, vector-free modification technologies, and AI would help make production cheaper.
Making CAR T therapies is an expensive business. A recent study suggested that producing a single batch can cost anywhere between $170,000 and $220,000, depending on the logistical, processing, and distribution steps involved.
The fundamental problem is that CAR T production is not a good fit for centralized manufacturing, according to Martin Bonamino, PhD, leader of the experimental cancer immunotherapy group at Brazil’s National Cancer Institute (INCA).
Anthropic, founded in 2021 by a team that departed OpenAI over differences in vision, closed a $3.5 billion fundraise earlier this year. That valued the company at $61.4 billion.
As artificial intelligence takes off, how do we efficiently integrate it into our lives and our work? Bridging the gap between promise and practice, Jann Spiess, an associate professor of operations, information, and technology at Stanford Graduate School of Business, is exploring how algorithms can be designed to most effectively support—rather than replace—human decision-makers.
This research, published on the arXiv preprint server, is particularly pertinent as prediction machines are integrated into real-world applications. Mounting empirical evidence suggests that high-stakes decisions made with AI assistance are often no better than those made without it.
From credit reports, where an overreliance on AI may lead to misinterpretation of risk scores, to social media, where models may depend on certain words to flag toxicity, leading to misclassifications—successful implementation lags behind the technology’s remarkable capabilities.
Fake AI installers for ChatGPT and InVideo deliver ransomware and info-stealers via SEO scams and social ads, targeting businesses.
Neuralink did not immediately return requests for comment outside regular business hours.
Semafor’s report corroborates earlier reporting from Bloomberg, which noted in April that the startup was looking to raise $500 million at an $8.5 billion pre-money valuation.
Neuralink last year received “breakthrough device” clearance from the U.S. FDA. Three people have so far received implants made by Neuralink. Earlier this month, a nonverbal patient posted a video about how he uses a Neuralink implant to edit and narrate YouTube videos with just his brain signals.
